Navigation Links
Pixantrone in Combination with Fludarabine, Dexamethasone and Rituximab Produces High Rates of Complete Remissions in Patients with Relapsed or Refractory Indolent Non-Hodgkins Lymphoma
Date:6/16/2011

02/(ISSN)1097-0142/earlyview">http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1097-0142/earlyview.

About Pixantrone

Pixantrone is a novel aza-anthracenedione that has distinct structural and physio-chemical properties that make its anti-tumor activity unique in this class of agents. Similar to anthracyclines, pixantrone inhibits Topo-isomerase II but unlike anthracyclines -- rather than intercalation with DNA -- pixantrone alkylates DNA -- forming stable DNA adducts with particular specificity for CpG-rich, hyper-methylated sites. These structural differences resulted in significantly enhanced anti-lymphoma activity compared to doxorubicin in preclinical models. In addition, the structural motifs on anthracycline-like agents that are responsible for the generation of oxygen free radicals and the formation of toxic drug-metal complexes have also been modified in pixantrone in an effort to prevent the binding of iron and perpetuation of superoxide production -- both of which are the putative mechanism for anthracycline induced acute cardiotoxicity. These novel pharmacologic differences may allow re-introduction of anthracycline-like potency in the treatment of relapsed/refractory diffuse large lymphoma without unacceptable rates of cardiotoxicity.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit www.CellTherapeutics.com.

Sign up for email alerts and get RSS feeds at our Web site,  

http://www.CellTherapeutics.com/investors_alert

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cell Therapeutics Targeting Potential Zevalin Label Expansion, Pixantrone and OPAXIO Drug Approvals to Grow Commercial Operations and Revenues in 2009
2. Low Occurrence of Severe Cardiac Side Effects Despite Extensive Prior Doxorubicin Treatment Reported in Pixantrone Pivotal Trial
3. Pixantrone Significantly Increases Complete Remissions, Overall Response Rates, Frequency of Durable Remissions and Progression Free Survival in Patients with Relapsed and Refractory Aggressive Non-Hodgkins Lymphoma
4. Cell Therapeutics Second Quarter Net Loss Decreases 54%; Pixantrone NDA Submitted to the FDA for Approval
5. Cell Therapeutics, Inc. (CTI) Advances Pixantrone Filing Process in Europe; Submits Pediatric Investigation Plan (PIP)
6. EMEA Validates Cell Therapeutics, Inc.s (CTI) Expanded Pixantrone Pediatric Investigation Plan (PIP)
7. New Pixantrone Data Presented at Meetings at American Society of Hematology Conference
8. FDA Provides Guidance for Design of Cell Therapeutics Pixantrone Pivotal Trial
9. Cell Therapeutics Initiates Pixantrone PIX-R Pivotal Trial for Treatment of Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
10. FDA Sets Meeting Date in Early June to Discuss Re-submission of Pixantrone NDA for Accelerated Approval
11. Oncolytics Biotech Inc. Completes Dose Escalation in Combination REOLYSIN(R)/Docetaxel Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)...  Sangamo BioSciences, Inc. (NASDAQ: SGMO ) ... accomplishments. For the second quarter ended ... of $7.0 million, or $0.10 per share, compared to ... share, for the same period in 2013. As of ... marketable securities and interest receivable of $236.7 million. ...
(Date:7/23/2014)... ANGELES , July 23, 2014 /PRNewswire-iReach/ -- Think ... cognitive performance for the long term. They are the ... edge of sustained energy as an alternative to the ... Think Drinks on Indiegogo on July 29, 2014, with ... 30-day campaign. Photo - http://photos.prnewswire.com/prnh/20140723/129697 ...
(Date:7/23/2014)...  Having the right people at the table for ... growth and achieving clinical and operational goals. The 22 ... July 20-22, 2014, in San Diego ... healthcare experts discussing how partnerships have positively impacted their ... Chief Executive Officer of Cape Regional Medical Center located ...
(Date:7/23/2014)... (PRWEB) July 23, 2014 DuPont Pioneer ... business as vice president of Agricultural Biotechnology (ABT), effective ... where he served most recently as president, chief executive ... and business leadership in the seed and crop protection ... Paul E. Schickler , president of DuPont Pioneer. ...
Breaking Biology Technology:Sangamo BioSciences Reports Second Quarter 2014 Financial Results 2Sangamo BioSciences Reports Second Quarter 2014 Financial Results 3Sangamo BioSciences Reports Second Quarter 2014 Financial Results 4Sangamo BioSciences Reports Second Quarter 2014 Financial Results 5Sangamo BioSciences Reports Second Quarter 2014 Financial Results 6Sangamo BioSciences Reports Second Quarter 2014 Financial Results 7Sangamo BioSciences Reports Second Quarter 2014 Financial Results 8Sangamo BioSciences Reports Second Quarter 2014 Financial Results 9truBrain Neuroscientists To Launch More Effective, Healthier Alternative To Energy Drinks On Indiegogo 2MSC and Cape Regional Medical Center Partner to Improve Cost, Quality and Outcomes 2DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 2DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 3
... Testing Management " Conference, Sept 23-25, that the American Filtration ... be seven short courses on September 22, 2008. Two of ... , ... Richfield, MN (PRWEB) August 8, ...
... ISELIN, N.J., Aug. 7 Pharmos Corporation,(Nasdaq: PARS ) ... The Company recorded a net loss of $2.7 million, or ... net loss of $4.6 million, or,$0.18 per share, in the ... June 30, 2008., The decrease in net loss for ...
... SOUTH SAN FRANCISCO, Calif., Aug. 7 Anesiva,Inc. (Nasdaq: ... the second quarter and six months ended June 30, ... advance for Anesiva as we,introduced Zingo(TM) in the U.S. ... executive officer. "In addition, I,m pleased,to report that our ...
Cached Biology Technology:Microfiltration Membrane and Ultrafiltration Membrane Training 2Microfiltration Membrane and Ultrafiltration Membrane Training 3Pharmos Corporation Reports 2008 Second Quarter Results 2Pharmos Corporation Reports 2008 Second Quarter Results 3Pharmos Corporation Reports 2008 Second Quarter Results 4Pharmos Corporation Reports 2008 Second Quarter Results 5Anesiva Announces Second Quarter 2008 Financial Results and Update 2Anesiva Announces Second Quarter 2008 Financial Results and Update 3Anesiva Announces Second Quarter 2008 Financial Results and Update 4Anesiva Announces Second Quarter 2008 Financial Results and Update 5Anesiva Announces Second Quarter 2008 Financial Results and Update 6Anesiva Announces Second Quarter 2008 Financial Results and Update 7Anesiva Announces Second Quarter 2008 Financial Results and Update 8
(Date:7/23/2014)... 2014 BCC Research ... GLOBAL MARKETS AND TECHNOLOGIES FOR SENSORS , the global ... grow to nearly $154.4 billion by 2020, with a ... image, flow, and level sensors segment is moving at ... http://photos.prnewswire.com/prnh/20140723/694805 ) , Sensors have become indispensable ...
(Date:7/23/2014)... Streptococcus mutans , one of the principal bacteria ... in its genetic material over time, possibly coinciding ... humanity. This is highlighted in a study ... (UAB) and the Laboratorio Nacional de Genmica para ... in Mexico who, for the first time, have ...
(Date:7/23/2014)... no cure exists for Alzheimer,s disease, the devastating ... But scientists are now reporting new progress on ... treatment, that shows promise as a potential oral ... Journal of Medicinal Chemistry . , Carlo ... in a healthy brain, the protein known as ...
Breaking Biology News(10 mins):Global Market for Sensors to Reach Nearly $154.4 Billion in 2020; Image Sensors Moving at 11.7% 2Global Market for Sensors to Reach Nearly $154.4 Billion in 2020; Image Sensors Moving at 11.7% 3Ancient genetic material from caries bacterium obtained for the first time 2
... Antarctic ice shelves to shrink and split apart, yielding thousands ... a new study in this week’s journal Science these floating ... miles across – are having a major impact on the ... ocean life, with thriving communities of seabirds above and a ...
... biofactories for the production of various beneficial human drugs, ... into mushrooms. , "There has always been a recognized ... for the mass production of commercially valuable proteins," said ... Chair in spawn science and professor of plant pathology ...
... Research Hospital have discovered how a single molecular “on switch” ... and memory capabilities to glucose production in the liver. ... transcription factor—a molecule that binds to a section of DNA ... specific protein for which it codes. CREB activates genes in ...
Cached Biology News:Antarctic icebergs -- Hotspots of ocean life 2Antarctic icebergs -- Hotspots of ocean life 3Modified mushrooms may yield human drugs 2St. Jude study shows genes play an unexpected role in their own activation 2
Anti-20S proteasome subunits alpha 1, 2, 3, 5, 6 & 7, clone MCP231 Immunogen: Dinitrophenylated proteasomes Molecular Weight: 29 and 32 kDa....
Anti-ADP-Ribosylation Factor 1, clone 3F1 Immunogen: Synthetic peptide corresponding to the C-terminal amino acid sequence of human ARF1. Available Date: 38495...
Myeloid Marker (BM-1)...
Request Info...
Biology Products: